CBF Cobra Bio-Man.

Cobra Bio-Manufacturing PLC
18 January 2007


For Immediate Release                                           18 January 2007



                           Cobra Biomanufacturing Plc

 Cobra signs agreement with Cequent to evaluate Cobra's ORT Technology for RNAi
                                    Delivery

Keele, UK, 18 January 2007 - UK based Cobra Biomanufacturing Plc (AIM:  CBF) has
signed an agreement with Cambridge, MA based Cequent Pharmaceuticals, Inc. to
develop a treatment for an inherited form of bowel tumour (Familial Adenomatous
Polyposis (FAP)). The treatment will incorporate Cobra's proprietary antibiotic
free maintenance technology (ORT) in conjunction with Cequent's proprietary
TransKingdom RNA interference (tkRNAi) technology.

Commenting on the contract, David Thatcher, CEO at Cobra, said: "We are
delighted to work with Cequent on this exciting project. Interference RNA (RNAi)
has great potential for medicine, and Cequent's tkRNAi technology clearly
represents an important breakthrough for the difficult, but exciting field of
RNAi delivery. We believe the combination of Cobra's ORT technology with
Cequent's in vivo delivery platform will have significant clinical benefit."

Peter Parker, President and CEO at Cequent, said: "Cobra has an excellent track
record of developing innovative solutions for molecular biology and biologic
therapy, and we look forward to collaborating with Cobra's outstanding
scientific team to evaluate their ORT technology for use in our therapeutic
tkRNAi bacteria."



Notes for Editors



About RNAi:

RNAi can potently and selectively silence any cellular gene or combination of
genes, making it an ideal approach to influence the behavior of cells where the
role of individual proteins is known. One, or more than one, gene can be
simultaneously silenced.

The knowledge of the human genome allows the progressive identification of
disease-causing genes. RNA interference offers a novel and highly efficient tool
to block the expression of such disease-causing genes. RNAi-based therapies are
expected to offer novel treatment solutions for a multitude of gene-based
disease states, including cancer, inflammatory disease, and viruses.

About FAP: Familial adenomatous polyposis: Abbreviated FAP. A genetic syndrome
characterized by the formation of hundreds of polyps in the colon and rectum
with colorectal cancer the inevitable consequence. 1:10,000 people are affected
in the United States. Polyps can also occur in the stomach, duodenum and the
terminal ileum. Patients require frequent removal of polyps via endoscopy and
often the entire colon is removed after puberty to avoid colon cancer formation.



ORT(R) Technology

ORT is a way of creating totally stable genetically engineered strains of
micro-organisms without the use of antibiotics or antibiotic genes. Other
technologies rely on either integrating the synthetic gene(s) into the bacterial
chromosome or using antibiotics and antibiotic resistance genes to amplify
replicating mini-chromosomes (called plasmids) containing the new genes. In the
vaccine field it has been known for 10 years that the former approach leads to
poor strain productivity and the latter to strain instability. Use of
antibiotics also creates the risk of passing on the antibiotic resistance genes
to pathogens in the environment. Such events have occurred naturally to create
MRSA super bug strains so ORT(R) strains are inherently safer for patients.
ORT(R) technology avoids these problems.



Live Oral ORT Technology

This application harnesses the advantages of conventional genetic engineering
with the safer ORT(R) strain stabilisation technology. This allows rapid and
simple construction of bacterial strains, capable of expressing massive
quantities of synthetic DNA, protein or RNA that can lead to beneficial effects
against disease targets without the fear of creating antibiotic resistant
strains which might be difficult to manage clinically.



About Cequent Pharmaceuticals Inc

Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company
developing new clinically compatible therapies based on RNA interference (RNAi).
Cequent is focusing its efforts on the pre-clinical development of products to
treat gastrointestinal diseases, including familial adenomatous polyposis (FAP),
inflammatory bowel disease and colon cancer.



Cequent has an exclusive license to a new technology, transkingdom
RNA-Interference (tkRNAi), which was invented and developed over the past 5
years at the GI Cancer Laboratory of Beth Israel Deaconess Medical Center,
Harvard Medical School.  In this technique, non-pathogenic bacteria are used as
engines to simultaneously produce and deliver RNAi. Through its use of tkRNAi in
various gastrointestinal diseases, Cequent is developing a portfolio of novel
therapeutic applications for RNAi - one of the most promising medical
breakthroughs of this decade.



About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.



Cobra was the first company to develop and gain GMP (Good Manufacturing
Practice) standard DNA manufacture in Europe, with specific expertise in DNA
medicines. A range of unique, patented technologies, underpins this revenue
generating business.



Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.2 million in May 2003 in
order to further expand capacity in Oxford UK.

www.cobrabio.com



Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements.  In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'.  Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research, which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.



For further information, please contact:


Cobra Biomanufacturing Plc                            Tel: +44 (0) 1782 714 181
David Thatcher, Chief Executive
Peter Coleman, Finance Director

Buchanan Communications                               Tel: +44 (0) 207 466 5000
Tim Anderson/Mark Court/Rebecca Skye Dietrich

Cequent Pharmaceuticals, Inc                             Tel: +1 (781) 771-5579

Caroline Grossman                                   caroline.grossman@gmail.com








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAEAKFXFSEXEFE

Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jun 2024 to Jul 2024

Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jul 2023 to Jul 2024